Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$21 Mln
P/E Ratio
--
P/B Ratio
0.23
Industry P/E
--
Debt to Equity
--
ROE
-0.35 %
ROCE
-35 %
Div. Yield
0 %
Book Value
308.39
EPS
-59.01
CFO
$-98.12 Mln
EBITDA
$-135.24 Mln
Net Profit
$-162.87 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Tenax Therapeutics (TENX)
| -16.96 | -20.06 | -19.30 | 41.60 | -82.45 | -64.41 | -63.13 |
|
BSE Sensex
| 1.48 | 4.01 | 3.03 | 8.65 | 11.66 | 20.20 | 11.03 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Tenax Therapeutics (TENX)
| -71.57 | -87.66 | -89.33 | -44.09 | 31.91 | 16.53 | -87.51 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 35.59 | 9,973.38 | 20.56 | 23.13 | |
| 288.99 | 8,956.07 | 23.48 | 58.42 | |
| 25.13 | 9,555.39 | -- | -28.77 | |
| 100.68 | 10,030.35 | 30.81 | 14.16 |
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that... have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina. Address: 101 Glen Lennox Drive, Chapel Hill, NC, United States, 27517 Read more
CEO, President & Director
Mr. Christopher T. Giordano
CEO, President & Director
Mr. Christopher T. Giordano
Headquarters
Chapel Hill, NC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Tenax Therapeutics Inc (TENX) stood at $ 97 Mln as on 31-Dec-24
The share price of Tenax Therapeutics Inc (TENX) is $5.14 (NASDAQ) as of 21-Apr-2025 16:00 EDT. Tenax Therapeutics Inc (TENX) has given a return of -82.45% in the last 3 years.
Tenax Therapeutics Inc (TENX) has a market capitalisation of $ 21 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Tenax Therapeutics Inc (TENX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Tenax Therapeutics Inc (TENX) and enter the required number of quantities and click on buy to purchase the shares of Tenax Therapeutics Inc (TENX).
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina. Address: 101 Glen Lennox Drive, Chapel Hill, NC, United States, 27517
The CEO & director of Mr. Christopher T. Giordano. is Tenax Therapeutics Inc (TENX), and CFO & Sr. VP is Mr. Christopher T. Giordano.
There is no promoter pledging in Tenax Therapeutics Inc (TENX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Tenax Therapeutics Inc. (TENX) | Ratios |
|---|---|
|
Return on equity(%)
|
-35.17
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Tenax Therapeutics Inc (TENX) was $0 Mln.
$-0.18
(
